Repligen Co. (NASDAQ:RGEN) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in Repligen Co. (NASDAQ:RGEN) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,667 shares of the biotechnology company’s stock after selling 1,034 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.12% of Repligen worth $9,921,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Andra AP fonden acquired a new stake in shares of Repligen in the second quarter worth $25,000. UMB Bank n.a. increased its holdings in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. raised its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Repligen during the second quarter worth about $33,000. Finally, nVerses Capital LLC purchased a new stake in shares of Repligen in the third quarter worth about $45,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is currently owned by insiders.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $148.50 on Wednesday. The stock has a market capitalization of $8.32 billion, a P/E ratio of -401.34, a P/E/G ratio of 4.53 and a beta of 0.96. The firm’s 50-day moving average price is $141.29 and its two-hundred day moving average price is $142.10. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business posted $0.23 EPS. Repligen’s revenue was up 9.7% on a year-over-year basis. As a group, sell-side analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on RGEN. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.